[1] |
FARDET L, PETERSEN I, NAZARETH I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years[J]. Rheumatology(Oxford),2011,50(11):1982-1990. DOI:10.1093/rheumatology/ker017.
|
[2] |
OVERMAN R A, YEH J Y, DEAL C L. Prevalence of oral glucocorticoid usage in the United States:a general population perspective[J]. Arthritis Care Res(Hoboken),2013,65(2):294-298. DOI:10.1002/acr.21796.
|
[3] |
LOCASCIO V, BONUCCI E, IMBIMBO B,et al. Bone loss in response to long-term glucocorticoid therapy[J]. Bone Miner,1990,8(1):39-51. DOI:10.1016/0169-6009(91)90139-Q.
|
[4] |
张学武,姚海红,梅轶芳,等. 全国多中心使用糖皮质激素风湿病患者骨质疏松调查[J]. 中华临床免疫和变态反应杂志,2017,11(3):277-284. DOI:10.3969/j.issn.1673-8705.2017.03.014.
|
[5] |
DING L L, HU J X, WANG D H,et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures network meta-analysis[J]. J Clin Endocrinol Metab,2020,105(3):600-613. DOI:10.1210/clinem/dgz023.
|
[6] |
PEREIRA R M R, PEREZ M O, PAULA A P,et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis:an update of Brazilian Society of Rheumatology(2020)[J]. Arch Osteoporos,2021,16(1):49. DOI:10.1007/s11657-021-00902-z.
|
[7] |
中国医师协会风湿免疫科医师分会,中华医学会风湿病学分会,中华医学会骨质疏松和骨矿盐疾病分会,等. 2020版中国糖皮质激素性骨质疏松症防治专家共识[J]. 中华内科杂志,2021,60(1):13-21. DOI:10.3760/cma.j.cn112138-20201102-00914.
|
[8] |
CHOTIYARNWONG P, MCCLOSKEY E V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment[J]. Nat Rev Endocrinol,2020,16(8):437-447. DOI:10.1038/s41574-020-0341-0.
|
[9] |
COMPSTON J. Glucocorticoid-induced osteoporosis:an update[J]. Endocrine,2018,61(1):7-16. DOI:10.1007/s12020-018-1588-2.
|
[10] |
BUCKLEY L, HUMPHREY M B. Glucocorticoid-induced osteoporosis[J]. N Engl J Med,2018,379(26):2547-2556. DOI:10.1056/nejmcp1800214.
|
[11] |
CHIODINI I, FALCHETTI A, MERLOTTI D,et al. Updates in epidemiology,pathophysiology and management strategies of glucocorticoid-induced osteoporosis[J]. Expert Rev Endocrinol Metab,2020,15(4):283-298. DOI:10.1080/17446651.2020.1772051.
|
[12] |
MATSUMOTO T, ENDO I. RANKL as a target for the treatment of osteoporosis[J]. J Bone Miner Metab,2021,39(1):91-105. DOI:10.1007/s00774-020-01153-7.
|
[13] |
ISERI K, IYODA M, WATANABE M,et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease:a randomized,controlled trial[J]. PLoS One,2018,13(3):e0193846. DOI:10.1371/journal.pone.0193846.
|
[14] |
HIROOKA Y, NOZAKI Y, INOUE A,et al. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment[J]. Bone Rep,2020,13:100293. DOI:10.1016/j.bonr.2020.100293.
|
[15] |
SAAG K G, WAGMAN R B, GEUSENS P,et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis:a multicentre,randomised,double-blind,active-controlled,double-dummy,non-inferiority study[J]. Lancet Diabetes Endocrinol,2018,6(6):445-454. DOI:10.1016/S2213-8587(18)30075-5.
|
[16] |
SAAG K G, PANNACCIULLI N, GEUSENS P,et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis:final results of a twenty-four-month randomized,double-blind,double-dummy trial[J]. Arthritis Rheumatol,2019,71(7):1174-1184. DOI:10.1002/art.40874.
|
[17] |
MATSUNO H. Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab,including those with rheumatoid arthritis and those receiving oral glucocorticoids[J]. DRUGS R D,2016,16(4):347-353. DOI:10.1007/S40268-016-0146-8.
|
[18] |
YANBEIY Z A, HANSEN K E. Denosumab in the treatment of glucocorticoid-induced osteoporosis:a systematic review and meta-analysis[J]. Drug Des Devel Ther,2019,13:2843-2852. DOI:10.2147/DDDT.S148654.
|
[19] |
RAUNER M, TAIPALEENMÄKI H, TSOURDI E,et al. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application[J]. J Clin Med,2021,10(4):787. DOI:10.3390/jcm10040787.
|
[20] |
孟迅吾,周学瀛. 协和代谢性骨病学[M]. 北京:中国协和医科大学出版社,2021:542-557.
|
[21] |
WIJENAYAKA A R, KOGAWA M, LIM H P,et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway[J]. PLoS One,2011,6(10):e25900. DOI:10.1371/journal.pone.0025900.
|
[22] |
VAN LIEROP A H, APPELMAN-DIJKSTRA N M, PAPAPOULOS S E. Sclerostin deficiency in humans[J]. Bone,2017,96:51-62. DOI:10.1016/J.BONE.2016.10.010.
|
[23] |
VAN LIEROP A H, HAMDY N A, PAPAPOULOS S E. Glucocorticoids are not always deleterious for bone[J]. J Bone Miner Res,2010,25(12):2796-2800. DOI:10.1002/JBMR.151.
|
[24] |
SATO A Y, CREGOR M, DELGADO-CALLE J,et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost/sclerostin[J]. J Bone Miner Res,2016,31(10):1791-1802. DOI:10.1002/JBMR.2869.
|
[25] |
YAO W, DAI W, JIANG L,et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength[J]. Osteoporos Int,2016,27(1):283-294. DOI:10.1007/S00198-015-3308-6.
|
[26] |
ACHIOU Z, TOUMI H, TOUVIER J,et al. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia[J]. Bone,2015,81:691-701. DOI:10.1016/J.BONE.2015.09.010.
|
[27] |
MARENZANA M, GREENSLADE K, EDDLESTON A,et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone[J]. Arthritis Rheum,2011,63(8):2385-2395. DOI:10.1002/ART.30385.
|
[28] |
IOLASCON G, MORETTI A, TORO G,et al. Pharmacological therapy of osteoporosis:what's new?[J]. Clin Interv Aging,2020,15:485-491. DOI:10.2147/CIA.S242038.
|
[29] |
MARKHAM A. Romosozumab:first global approval[J]. Drugs,2019,79(4):471-476. DOI:10.1007/s40265-019-01072-6.
|
[30] |
DAVIS K, DAVENPORT K, SCHOTS L. FDA Approves EVENITYTM(romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture[EB/OL]. [2021-07-20]. .
|
[31] |
JASCHKE N, HOFBAUER L C, GÖBEL A,et al. Evolving functions of Dickkopf-1 in cancer and immunity[J]. Cancer Lett,2020,482:1-7. DOI:10.1016/J.CANLET.2020.03.031.
|
[32] |
RACHNER T D, GOBEL A, BENAD-MEHNER P,et al. Dickkopf-1 as a mediator and novel target in malignant bone disease[J]. Cancer Lett,2014,346:172-177. DOI:10.1016/j.canlet.2014.01.010.
|
[33] |
HEILAND G R, ZWERINA K, BAUM W,et al. Neutralisation of DKK-1 protects from systemic bone loss during inflammation and reduces sclerostin expression[J]. Ann Rheum Dis,2010,69(12):2152-2159. DOI:10.1136/ard.2010.132852.
|
[34] |
TAI N, INOUE D. Anti-Dickkopf1(DKK1) antibody as a bone anabolic agent for the treatment of osteoporosis[J]. Clin Calcium,2014,24(1):75-83.
|
[35] |
GLANTSCHNIG H, SCOTT K, HAMPTON R,et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody[J]. J Pharmacol Exp Ther,2011,338(2):568-578. DOI:10.1124/jpet.111.181404.
|
[36] |
LIU M, KURIMOTO P, ZHANG J,et al. Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss[J]. J Dent Res,2018,97(9):1031-1038. DOI:10.1177/0022034518766874.
|
[37] |
FLORIO M, GUNASEKARAN K, STOLINA M,et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair[J]. Nat Commun,2016,7:11505. DOI:10.1038/ncomms11505.
|
[38] |
IYER S P, BECK J T, STEWART A K,et al. A PhaseⅠB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events[J]. Br J Haematol,2014,167(3):366-375. DOI:10.1111/bjh.13056.
|
[39] |
KATO T, KHANH V C, SATO K,et al. Elevated expression of DKK-1 by glucocorticoid treatment impairs bone regenerative capacity of adipose tissue-derived mesenchymal stem cells[J]. Stem Cells Dev,2018,27(2):85-99. DOI:10.1089/scd.2017.0199.
|
[40] |
COLDITZ J, THIELE S, BASCHANT U,et al. Osteogenic DKK1 mediates glucocorticoid-induced but not arthritis-induced bone loss[J]. J Bone Miner Res,2019,34(7):1314-1323. DOI:10.1002/JBMR.3702.
|